Journal of Asthma最新文献

{"title":"Predicting prolonged hospitalization in asthma patients: model development and external validation.","authors":"Xinkai Ma, Peiqi Li, Yupeng Li, Yanqing Xing, Zhen Ma, Chuangchuan Dong, Liting Feng, Rujie Huo, Fei Hu, Yanting Dong, Jie Chen, Jiali Zhang, Xinrui Tian","doi":"10.1080/02770903.2025.2500081","DOIUrl":"10.1080/02770903.2025.2500081","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to develop and validate a machine learning (ML) model to predict prolonged hospitalization in asthma patients.</p><p><strong>Patients and methods: </strong>This retrospective cohort study included patients with asthma as the primary diagnosis. We randomly divided 2820 asthma patients from Beth Israel Deaconess Medical Center into a training set and an internal validation set (in an 8:2 ratio), and used 1714 asthma patients from 208 other hospitals in the United States as an external validation cohort. Prolonged hospitalization was the primary outcome. Feature selection was conducted using LASSO regression, univariate logistic regression, and multivariate logistic regression analyses. Nine ML algorithms were employed to develop predictive models.</p><p><strong>Results: </strong>Based on discrimination, calibration, and clinical utility, the Extreme Gradient Boosting (XGBoost) model demonstrated the best overall performance. The nine most important predictors in the model were age, oxygen saturation (SpO2), red blood cell count, hemoglobin count, comorbid pneumonia, chronic obstructive pulmonary disease (COPD), congestive heart failure, anxiety, and use of invasive mechanical ventilation. The XGBoost model achieved an area under the receiver operating characteristic curve (AUC) of 0.829 and a Cohen's Kappa value of 0.439 in the internal validation set, and an AUC of 0.745 and a Cohen's Kappa value of 0.315 in the external validation set. The decision curve analysis indicated good clinical utility of the model.</p><p><strong>Conclusions: </strong>The XGBoost model can effectively predict prolonged hospitalization in asthma patients.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1616-1626"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linking anemia to asthma: maternal, childhood and adult perspectives from a meta-analysis of 20 studies.","authors":"Kaiwen Zheng, Xiang Wang","doi":"10.1080/02770903.2025.2499837","DOIUrl":"10.1080/02770903.2025.2499837","url":null,"abstract":"<p><strong>Background: </strong>Anemia has been implicated as a potential risk factor for asthma across different life stages, yet evidence remains inconsistent.</p><p><strong>Objective: </strong>This meta-analysis (CRD420251008733) aimed to evaluate the associations between maternal anemia and offspring asthma, childhood anemia and asthma, and adult anemia and asthma.</p><p><strong>Methods: </strong>We searched PubMed, Embase, Web of Science, and Cochrane Library, identifying 20 observational studies. Study quality was assessed using the Newcastle-Ottawa Scale (NOS) and Agency for Healthcare Research and Quality (AHRQ) checklist. Heterogeneity, sensitivity, and publication bias were explored through subgroup analyses, sensitivity tests, and Egger's test. Meta-analysis performed using Stata 17.</p><p><strong>Results: </strong>Twenty studies involving over 4499364 participants were included. The results showed pooled OR for the association between anemia and asthma (OR = 1.55, 95% CI: 1.36-1.77). Maternal anemia during pregnancy was associated with a modest increase in offspring asthma risk (OR = 1.19, 95% CI: 1.02-1.38), adult anemia was also linked to asthma (OR = 1.94, 95% CI: 1.14-3.30). Childhood anemia showed a stronger association with asthma (OR = 2.22, 95% CI: 1.65-2.99), though Egger's test (<i>p</i> = 0.041) suggested publication bias, with an adjusted OR of 2.03 (95% CI: 1.51-2.74).</p><p><strong>Conclusions: </strong>Anemia is significantly associated with an increased risk of asthma, particularly in children. These findings suggest a potential role for anemia screening in asthma management.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1459-1471"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence in asthma health literacy: a comparative analysis of ChatGPT versus Gemini.","authors":"Simon Høj, Vibeke Backer, Charlotte Suppli Ulrik, Torben Sigsgaard, Howraman Meteran","doi":"10.1080/02770903.2025.2495729","DOIUrl":"10.1080/02770903.2025.2495729","url":null,"abstract":"<p><strong>Background: </strong>Asthma is a complex and heterogeneous chronic disease affecting over 300 million individuals worldwide. Despite advances in pharmacotherapy, poor disease control remains a major challenge, necessitating innovative approaches to patient education and self-management. Artificial intelligence driven chatbots, such as ChatGPT and Gemini, have the potential to enhance asthma care by providing real-time, evidence-based information. As asthma management moves toward personalized medicine, AI could support individualized education and treatment guidance. However, concerns remain regarding the accuracy and reliability of AI-generated medical content.</p><p><strong>Objective: </strong>This study evaluated the accuracy of ChatGPT (version 4.0) and Gemini (version 1.2) in providing asthma-related health information using the Patient-completed Asthma Knowledge Questionnaire, a validated asthma literacy tool.</p><p><strong>Methods: </strong>A cross-sectional study was conducted in which both AI models answered 54 standardized asthma-related items. Responses were classified as correct or incorrect based on alignment with validated clinical knowledge. Accuracy was assessed using descriptive statistics, Cohen's kappa for inter-model agreement, and chi-square tests for comparative performance.</p><p><strong>Results: </strong>ChatGPT achieved an accuracy of 96.3% (52/54 correct; 95% CI: 87.5%-99.0%), while Gemini scored 92.6% (50/54 correct; 95% CI: 82.5%-97.1%), with no statistically significant difference (<i>p</i> = 0.67). Cohen's kappa demonstrated near-perfect agreement for ChatGPT (κ = 0.91) and strong agreement for Gemini (κ = 0.82).</p><p><strong>Conclusion: </strong>ChatGPT and Gemini demonstrated high accuracy in delivering asthma-related health information, supporting their potential as adjunct tools for patient education. AI models could potentially play a role in personalized asthma management by providing tailored treatment guidance and improving patient engagement.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1560-1566"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occupational risk factors for asthma exacerbation in adults: a five-year follow-up of the Norwegian Telemark study cohort.","authors":"Nikola Zivadinovic, Keson Jaioun, Geir Klepaker, Anthony Wagstaff, Kjell Torén, Paul K Henneberger, Johny Kongerud, Regine Abrahamsen, Anne Kristin Møller Fell","doi":"10.1080/02770903.2025.2500077","DOIUrl":"10.1080/02770903.2025.2500077","url":null,"abstract":"<p><strong>Objectives: </strong>Asthma exacerbation due to occupational exposure is highly prevalent among adults with asthma. This study assessed the association between occupational risk factors and asthma exacerbation and estimated the impact of asthma exacerbations on job change, sick leave and work ability.</p><p><strong>Methods: </strong>In a prospective study of respiratory health in Telemark, Norway, 1857 adult participants with physician-diagnosed asthma were invited to participate in a follow-up survey. Among those who responded, 740 were found eligible for this study. Participants were categorized into overall, mild, and severe asthma exacerbation groups based on self-reports of hospitalization, doctor or emergency visits for breathing difficulties, or increased or new use of lung medications. Logistic regression, adjusted for age, sex, and smoking, was used to assess associations between self-reported asthma exacerbation and exposure to VGDF, job exposure matrix (N-JEM) data, job change, sick leave, and work ability.</p><p><strong>Results: </strong>Asthma exacerbation occurred in 140 (19%) responders; 83 had mild exacerbations and 57 severe exacerbations. Severe exacerbation was associated with daily VGDF exposure (OR 2.57, 95% CI 1.15-5.78) and accidental peak exposure to irritants (OR 4.62, 95% CI 1.13-18.85). Both overall and severe exacerbation were associated with job changes (OR 5.40, 1.26-5.65; OR 3.06, 1.16-8.07), sick leave (OR 1.94, 1.33-2.85; OR 2.78, 1.57-4.92), and reduced work ability (OR 1.61, 1.04-2.49; OR 2.17, 1.18-3.98).</p><p><strong>Conclusion: </strong>Asthma exacerbation was associated with VGDF exposure and some N-JEM occupational exposures. Reducing workplace exposure may decrease job-change, sick leave, and improve work ability in individuals with asthma exacerbation.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1608-1615"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing gaps in asthma management during childbearing age and pregnancy: insights from a survey of Italian physicians and patients.","authors":"Manuela Latorre, Cristina Cardini, Oliviero Rossi, Enrico Heffler, Diego Bagnasco, Gianenrico Senna, Gabriella Guarnieri, Francesco Blasi, Giorgio Walter Canonica, Pierluigi Paggiaro","doi":"10.1080/02770903.2025.2494222","DOIUrl":"10.1080/02770903.2025.2494222","url":null,"abstract":"<p><strong>Background: </strong>Asthma is a common condition among women of childbearing age, requiring careful management, particularly during pregnancy. Despite existing guidelines, significant gaps remain in asthma management during pregnancy, notably for women with moderate-to-severe asthma.</p><p><strong>Aim: </strong>This study aimed to explore the awareness, limitations, and challenges of asthma management during childbearing age and pregnancy from both asthmatic women (AW) and physician perspectives in Italy. Additionally, it sought to identify unmet needs and collect real-life experiences from Italian centers specialized in severe asthma care.</p><p><strong>Methods: </strong>An anonymous online survey was disseminated through scientific networks and patient associations. Separate questionnaires were developed for doctors and AW by a task force of specialists.</p><p><strong>Results: </strong>76 doctors and 54 AW completed the survey, with 70% of AW reporting moderate-to-severe asthma. While most physicians had experience managing asthma in pregnancy, 40% lacked systematic collaboration with gynecologists recognizing the need for integrated care. Despite guidelines supporting asthma medication continuity, 60% of doctors reported discontinuing treatments due to perceived risks. However, surveyed AW generally expressed greater confidence in medication safety. Physicians and AW highlighted the lack of pre-pregnancy counseling, with 55% of AW reporting they had never discussed pregnancy plans when starting asthma treatment. Both groups emphasized the need for improved interdisciplinary collaboration and structured asthma care pathways during pregnancy.</p><p><strong>Conclusions: </strong>This study reveals significant gaps in asthma management for women of childbearing age and during pregnancy, especially those with moderate-to-severe asthma. Improving outcomes requires better education for patients and healthcare providers, along with a structured multidisciplinary network.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1537-1546"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of tezepelumab therapy on perceived asthma triggers: a multicenter real-life study.","authors":"Andrea Portacci, Giulia Scioscia, Silvano Dragonieri, Maria Aliani, Ernesto Lulaj, Francesca Montagnolo, Pietro Magaletti, Piera Soccio, Luciana Salerno, Donato Lacedonia, Giovanna Elisiana Carpagnano","doi":"10.1080/02770903.2025.2495725","DOIUrl":"10.1080/02770903.2025.2495725","url":null,"abstract":"<p><strong>Objective: </strong>Asthma exacerbations are often triggered by factors such as respiratory infections, allergens, exercise, and airway irritants, significantly affecting patients' respiratory symptoms and quality of life. Effective management of triggers is crucial in severe asthma care. Tezepelumab, an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, can effectively reduce severe asthma exacerbations and symptoms burden. However, its impact on patients' perception of trigger-related symptoms remains underexplored.</p><p><strong>Methods: </strong>We conducted an observational, multicenter study involving 30 severe asthma patients starting tezepelumab 210 mg every 4 wk. Asthma triggers were assessed with the Asthma Triggers Inventory (ATI), while respiratory symptoms and HRQoL were evaluated using the Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), and Asthma Quality of Life Questionnaire (AQLQ). Data were collected at baseline (T0) and after 3 months of treatment (T3).</p><p><strong>Results: </strong>At T3, patients demonstrated a significant reduction in the impact of asthma triggers as well as improvements in the perception of triggers effects on HRQoL. Specific improvements were observed in the \"air pollution/irritants\" and \"infection\" domains of the ATI. Correlation analysis revealed a significant association between ATI and AQLQ changes over time.</p><p><strong>Conclusion: </strong>Tezepelumab positively impacts patients' perception of asthma triggers and their HRQoL, supporting its role in managing triggers hypersensitivity as a treatable trait in severe asthma. Further research is warranted to investigate underlying mechanisms and long-term effects.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1567-1574"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity-driven airway eosinophilia and neutrophilia in asthma.","authors":"Joseph Zouein, Loretta G Que, Jennifer L Ingram","doi":"10.1080/02770903.2025.2505464","DOIUrl":"10.1080/02770903.2025.2505464","url":null,"abstract":"<p><strong>Objective: </strong>Asthma patients with comorbid obesity tend to have more severe, difficult-to-control asthma than lean asthma patients. This increase in asthma severity may be due, in part, to obesity-related adipokines, such as leptin, which contribute to airway hyperresponsiveness, sustained subclinical chronic inflammation, and treatment resistance. This narrative literature review aims to elucidate the differences in airway eosinophilia and neutrophilia profiles between asthma patients with and without obesity.</p><p><strong>Methods: </strong>A PubMed search of full journal articles published between 1992 and 2024 was performed in April 2024 using the terms \"asthma\", \"tissue eosinophilia\" and \"obesity\" combined with the Boolean operator \"AND\". Articles detailing airway tissue eosinophilia and neutrophilia in asthma patients or mice were included. Only articles in English were included.</p><p><strong>Results: </strong>To date, several studies have reported increased airway tissue eosinophilia in obese mouse asthma models (four studies) and in asthma patients with obesity (three studies). Airway tissue eosinophilia in asthma patients with obesity is driven by altered and elevated levels of adipokines, pro-inflammatory cytokines, and eosinophil-stimulating chemokines such as eotaxin. Leptin and eotaxin levels are increased in asthma with obesity and contribute to enhanced eosinophil recruitment, migration, adhesion to airway smooth muscles and fibroblasts, and reduced apoptosis.</p><p><strong>Conclusions: </strong>Airway tissue eosinophilia is an important feature of obesity-associated asthma. Airway tissue eosinophilia is mainly driven by obesity-related homeostatic changes. These increased airway tissue eosinophils contribute to a more severe disease.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1472-1482"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inpatient Electronic-Consults for Asthma Hospitalization Improve Outpatient Outcomes.","authors":"Linh-An C Tuong, Allison Ramsey, Sara Patrawala, Richard Kraude, Peter Capucilli, Denise Sanchez-Tejera, S Shahzad Mustafa","doi":"10.1080/02770903.2025.2548534","DOIUrl":"10.1080/02770903.2025.2548534","url":null,"abstract":"<p><strong>Objective: </strong>Asthma exacerbations frequently lead to systemic corticosteroid use, emergency department (ED) visits, and hospitalizations. While specialist care can improve asthma outcomes, a critical gap often exists between inpatient hospitalization and outpatient follow-up. This study measured the clinical impact of an allergy/immunology (A/I) electronic consult (e-consult) for patients hospitalized for asthma exacerbation.</p><p><strong>Methods: </strong>In this quality improvement project, all patients admitted for asthma received an A/I e-consult addressing asthma controller therapy and outpatient follow-up. Clinical outcomes were tracked for the subsequent year. Results are reported with descriptive statistics, and a paired T-test was used to compare groups.</p><p><strong>Results: </strong>133 patients were enrolled; mean age 28.9 ± 23.3 years, 76 (57%) females, 64 (48%) Black, and 36 (27%) Hispanic. 73 (55%) patients were on asthma maintenance therapy, whereas 60 (45%) were on monotherapy with a short-acting beta agonist (SABA). In the year prior to hospital admission, 43 (32%) had been seen in the ED/UC and 73 (55%) had been previously hospitalized. The mean courses of SCS was 2.5 ± 2.2. Following the inpatient e-consult, 77 (58%) followed up as scheduled, and there was a decrease in hospitalization (mean 1.38 ± 0.11 to 0.42 ± 0.10, <i>p</i><.0001), ED/UC visits (mean 1.35 ± 0.23 to 0.70 ± 0.15, <i>p</i>=.0025), and SCS courses (mean 2.74 ± 0.25 to 1.43 ± 0.25, <i>p</i><.0001). An inpatient e-consult improved outcomes regardless of follow-up status for both pediatric and adult patients.</p><p><strong>Conclusion: </strong>Inpatient A/I e-consults for asthma exacerbations decreased SCS use and healthcare utilization, including inpatient hospitalization, in both pediatric and adult patients.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-7"},"PeriodicalIF":1.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"STOML2 knockdown inhibits inflammation and airway remodeling of PDGF-BB-induced airway smooth-muscle cells by the MAPK pathway.","authors":"Zhen Li, Songbai Zhu","doi":"10.1080/02770903.2025.2546358","DOIUrl":"10.1080/02770903.2025.2546358","url":null,"abstract":"<p><strong>Objective: </strong>Asthma is a chronic inflammatory airway disease characterized by airway inflammation and remodeling. Abnormal proliferation and migration of human airway smooth muscle cells (HASMCs), induced by platelet-derived growth factor BB (PDGF-BB), are associated with the occurrence and progression of asthma. In this study, we aim to investigate the expression and molecular mechanisms of stomatin-like protein-2 (STOML2) in airway remodeling in asthma.</p><p><strong>Methods: </strong>PDGF-BB-stimulated HASMCs were used as the asthma cell model. STOML2 expression levels in the serum of patients with asthma and healthy controls were measured using qRT-PCR. Additionally, qRT-PCR and western blotting were used to measure STOML2, E-cadherin, and N-cadherin expression in HASMCs. Extracellular matrix components were detected by western blot assay. The viability and migration of HASMCs were analyzed using MTT and Transwell assays. Tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and IL-6 contents were evaluated using the corresponding kits. The key molecules of the p38 mitogen-activated protein kinase (p38 MAPK) pathway (p38 and p38) were determined using western blotting.</p><p><strong>Results: </strong>Increased STOML2 expression was observed in both patients with asthma and PDGF-BB-treated HASMCs. STOML2 knockdown inhibits STOML2 expression in HASMCs. PDGF-BB induced proliferation, migration, extracellular matrix deposition, inflammatory responses, and p38 MAPK pathway activation in HASMCs. However, the opposite effects were observed following STOML2 knockdown or SB-203580 treatment, respectively. Furthermore, P79350 treatment reversed the effect of STOML2 knockdown.</p><p><strong>Conclusions: </strong>Our results showed that silencing STOML2 inhibits inflammation and airway remodeling in PDGF-BB-stimulated HASMCs via the p38 MAPK pathway. Thus, STOML2 is a promising therapeutic target for the treatment of asthma.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the effects of two low-dose budesonide suspension nebulization treatments on asthma among young children: a multicenter study.","authors":"Pingbo Zhang, Yixiao Bao, Xiaojian Zhou, Yanming Lu, Bo Ding, Li Hua, Lili Zhong, Dan Liu, Jing Liu, Deyu Zhao, Zhongping Zhang, Lina Zhen, Suping Tang, Wenhui Jiang, Caifeng Zhang, Zhou Fu, Zehui Ye, Li Dong, Rongfang Zhang, Xuan Liang, Ning Wang, Long Zhao, Ya Luo, Zhaobo Shen, Ping Kang, Mengli Ren, Jie Shao","doi":"10.1080/02770903.2025.2539810","DOIUrl":"10.1080/02770903.2025.2539810","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of treatment with nebulized budesonide inhalation suspension (BIS) at dosages of 500 µg/day and 250 µg/day on mild to moderate asthma in young children.</p><p><strong>Methods: </strong>This was a randomized, parallel group, open-label study at 19 Chinese clinical sites. A total of 340 patients (4-7 years) with mild to moderate persistent pediatric asthma were randomly and evenly divided into the 500-µg group (BIS 500 µg/day) and the 250-µg group (BIS 250 µg/day); 323 patients completed the study. The Children-Asthma Control Test (C-ACT), asthma control, Pediatric Asthma Quality of Life Questionnaire (PAQLQ), pulmonary function tests (PFT), additional asthma-related therapy, and adverse effects (AEs) were compared after 1, 3, and 6 months of treatment between groups.</p><p><strong>Results: </strong>There were no statistically significant differences in C-ACT scores, level of asthma control, PAQLQ scores, PFT parameters, additional medications and AE occurrences from baseline to 6 months post-treatment between the two groups (all <i>p</i> > 0.05). Compared with baseline values, both groups showed improvements in C-ACT and PAQLQ scores, the rate of well-controlled asthma, and PFT parameters (all <i>p</i> < 0.05). The cumulative number of unplanned outpatient visits (50 vs. 49) and hospitalizations (3 vs. 0) in the 250-µg group was higher than that in the 500-µg group (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>The lower dosage of 250 µg/day BIS was found to be as effective as 500 µg/day BIS. For young children with mild to moderate persistent asthma who have well-controlled, a lower dose of BIS treatment can be chosen.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.3,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144742177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}